Related Experiment Video
Updated: Mar 24, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Heart Failure With Preserved Ejection Fraction
Insights
Heart failure with preserved ejection fraction (HFpEF) is a growing global health burden. Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF lacks effective treatments, highlighting distinct pathophysiologies.
Area of Science:
- Cardiology
- Internal Medicine
- Public Health
Background:
- Heart failure (HF) significantly impacts global morbidity and healthcare costs.
- Heart failure with preserved ejection fraction (HFpEF) drives increasing HF prevalence, linked to obesity, hypertension, and metabolic syndrome.
- Despite advances in heart failure with reduced ejection fraction (HFrEF) treatments, HFpEF outcomes remain unchanged, indicating fundamental differences.
Purpose of the Study:
- To review the current understanding of HFpEF pathophysiology.
- To discuss diagnostic and therapeutic strategies for HFpEF.
- To outline future research directions for HFpEF.
Main Methods:
- Literature review of current research on HFpEF.
- Analysis of pathophysiological mechanisms specific to HFpEF.
- Synthesis of diagnostic criteria and treatment approaches for HFpEF.
Main Results:
- HFpEF pathophysiology involves distinct mechanisms compared to HFrEF.
- Current HFrEF therapies are largely ineffective for HFpEF.
- Diagnostic challenges persist for HFpEF, necessitating further investigation.
Conclusions:
- HFpEF represents a distinct clinical entity requiring tailored management strategies.
- Understanding HFpEF pathophysiology is crucial for developing effective therapies.
- Future clinical investigations should focus on novel diagnostic and therapeutic targets for HFpEF.
Abstract:
Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the world and continues to increase in prevalence at an alarming rate. Most of this increasing burden is related to the rapidly expanding population of HF with preserved ejection fraction (HFpEF), largely driven by the increasing rates of obesity, hypertension, and metabolic syndrome in western countries. In the last 3 decades, there have been tremendous advances in treating patients with HF with reduced ejection fraction (HFrEF), with essentially no change in outcomes for HFpEF. The lack of efficacy for established HFrEF therapies in HFpEF underscores the fundamental differences between both these phenotypically distinct forms of HF. In this review, we will summarize the current understanding of the pathophysiology of HFpEF, discuss diagnostic and therapeutic strategies, and provide future avenues to direct clinical investigation.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
Heart Failure III: Clinical Manifestations
Heart Failure V: Medical Management

